Exploring Innovative Therapies
NeuroSigma, Inc. is developing trigeminal nerve stimulation (TNS) for a variety of disorders, including epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD) Lennox-Gastaut syndrome (LGS) and traumatic brain injury (TBI). NeuroSigma’s unique TNS technology can be delivered via the non-invasive Monarch external trigeminal nerve stimulation (eTNS™) system or the minimally-invasive subcutaneous trigeminal nerve stimulation (sTNS™) system which is currently under development.
The Monarch™ eTNS system is easy to use and convenient.
This cell phone sized device is now available as adjunctive treatment of epilepsy and depression in the European Union and Canada and as and adjunctive treatment for epilepsy in Australia.
CAUTION: In the United States, both eTNS™ and sTNS™ are investigational devices and are limited by Federal (or United States) law to investigational use.